313 related articles for article (PubMed ID: 31181537)
21. Prevalence and breakdown of non-small cell lung cancer BRAF driver mutations in a large UK cohort.
Lim GHT; Balbi KJ; Poskitt B; Bennett P; Moore DA
Lung Cancer; 2022 Nov; 173():71-74. PubMed ID: 36156323
[TBL] [Abstract][Full Text] [Related]
22. Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with
Ortiz-Cuaran S; Mezquita L; Swalduz A; Aldea M; Mazieres J; Leonce C; Jovelet C; Pradines A; Avrillon V; Chumbi Flores WR; Lacroix L; Loriot Y; Westeel V; Ngo-Camus M; Tissot C; Raynaud C; Gervais R; Brain E; Monnet I; Giroux Leprieur E; Caramella C; Mahier-Aït Oukhatar C; Hoog-Labouret N; de Kievit F; Howarth K; Morris C; Green E; Friboulet L; Chabaud S; Guichou JF; Perol M; Besse B; Blay JY; Saintigny P; Planchard D
Clin Cancer Res; 2020 Dec; 26(23):6242-6253. PubMed ID: 32859654
[TBL] [Abstract][Full Text] [Related]
23. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
[TBL] [Abstract][Full Text] [Related]
24. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
25. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
Joshi M; Rice SJ; Liu X; Miller B; Belani CP
PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985
[TBL] [Abstract][Full Text] [Related]
26. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
Martín Martorell P; Huerta M; Compañ Quilis A; Abellán R; Seda E; Blesa S; Chaves FJ; Dualde Beltrán D; Roselló Keränen S; Franco J; Insa A
Clin Lung Cancer; 2017 Nov; 18(6):e395-e402. PubMed ID: 28550959
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
Dudnik E; Bar J; Peled N; Bshara E; Kuznetsov T; Cohen AY; Shochat T; Nechushtan H; Onn A; Agbarya A; Moskovitz M; Keren S; Popovits-Hadar N; Urban D; Mishaeli M; Rabinovich NM; Brenner R; Zer A; Rotem O; Roisman LC; Wollner M;
Clin Lung Cancer; 2019 Jul; 20(4):278-286.e1. PubMed ID: 31060855
[TBL] [Abstract][Full Text] [Related]
28. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
29. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.
Gautschi O; Milia J; Cabarrou B; Bluthgen MV; Besse B; Smit EF; Wolf J; Peters S; Früh M; Koeberle D; Oulkhouir Y; Schuler M; Curioni-Fontecedro A; Huret B; Kerjouan M; Michels S; Pall G; Rothschild S; Schmid-Bindert G; Scheffler M; Veillon R; Wannesson L; Diebold J; Zalcman G; Filleron T; Mazières J
J Thorac Oncol; 2015 Oct; 10(10):1451-7. PubMed ID: 26200454
[TBL] [Abstract][Full Text] [Related]
30. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
Lopez-Chavez A; Thomas A; Rajan A; Raffeld M; Morrow B; Kelly R; Carter CA; Guha U; Killian K; Lau CC; Abdullaev Z; Xi L; Pack S; Meltzer PS; Corless CL; Sandler A; Beadling C; Warrick A; Liewehr DJ; Steinberg SM; Berman A; Doyle A; Szabo E; Wang Y; Giaccone G
J Clin Oncol; 2015 Mar; 33(9):1000-7. PubMed ID: 25667274
[TBL] [Abstract][Full Text] [Related]
31. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
32. Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.
Negrao MV; Raymond VM; Lanman RB; Robichaux JP; He J; Nilsson MB; Ng PKS; Amador BE; Roarty EB; Nagy RJ; Banks KC; Zhu VW; Ng C; Chae YK; Clarke JM; Crawford JA; Meric-Bernstam F; Ignatius Ou SH; Gandara DR; Heymach JV; Bivona TG; McCoach CE
J Thorac Oncol; 2020 Oct; 15(10):1611-1623. PubMed ID: 32540409
[TBL] [Abstract][Full Text] [Related]
33. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
34. BRAF-mutations in non-small cell lung cancer.
Brustugun OT; Khattak AM; Trømborg AK; Beigi M; Beiske K; Lund-Iversen M; Helland Å
Lung Cancer; 2014 Apr; 84(1):36-8. PubMed ID: 24552757
[TBL] [Abstract][Full Text] [Related]
35. A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker.
Turshudzhyan A; Vredenburgh J
Curr Oncol; 2020 Dec; 28(1):196-202. PubMed ID: 33704186
[TBL] [Abstract][Full Text] [Related]
36. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation.
Ding X; Zhang Z; Jiang T; Li X; Zhao C; Su B; Zhou C
Cancer Med; 2017 Mar; 6(3):555-562. PubMed ID: 28135039
[TBL] [Abstract][Full Text] [Related]
38. Encorafenib plus binimetinib in patients with
Riely GJ; Ahn MJ; Felip E; Ramalingam SS; Smit EF; Tsao AS; Alcasid A; Usari T; Wissel PS; Wilner KD; Johnson BE
Future Oncol; 2022 Mar; 18(7):781-791. PubMed ID: 34918546
[TBL] [Abstract][Full Text] [Related]
39. The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients.
Lin Q; Zhang H; Ding H; Qian J; Lizaso A; Lin J; Han-Zhang H; Xiang J; Li Y; Zhu H
J Transl Med; 2019 Aug; 17(1):298. PubMed ID: 31470866
[TBL] [Abstract][Full Text] [Related]
40. Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Chen M; Xu Y; Zhao J; Zhong W; Zhang L; Bi Y; Wang M
EBioMedicine; 2019 Apr; 42():304-310. PubMed ID: 30878600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
